161 results on '"Rossi Giuseppe"'
Search Results
2. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
3. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
4. Decision-making and risk-taking in forensic and non-forensic patients with schizophrenia spectrum disorders: A multicenter European study
5. Effective Cardiac Index and Systemic-Pulmonary Collaterals Evaluated by Cardiac Magnetic Resonance Late After Fontan Palliation
6. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
7. Neoplasms derived from plasmacytoid dendritic cells
8. Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
9. Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
10. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
11. microRNA Aberrations in Waldenström Macroglobulinemia
12. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
13. Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction
14. Folliculocentric B-cell–rich follicular dendritic cells sarcoma: a hitherto unreported morphological variant mimicking lymphoproliferative disorders
15. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
16. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors
17. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
18. Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)
19. SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)
20. Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial
21. Worldwide Examination of Patients with CLL Hospitalized for COVID-19
22. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
23. -G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study
24. Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC
25. Elective Surgery for Giant Bullous Emphysema: A 5-Year Clinical and Functional Follow-up
26. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials
27. Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy
28. Regional cerebral hypoperfusion in patients with celiac disease
29. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
30. Isolated Bone Marrow Manifestation of HIV-Associated Hodgkin Lymphoma
31. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection
32. Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin
33. Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
34. Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels
35. Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases
36. Impaired Sars-Cov-2 Specific Antibody Responses in Patients Treated with Anti-CD20 Antibodies
37. Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number
38. Waldenström’s Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells
39. FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88
40. Behavioral and neurobiological correlates of childhood apraxia of speech in Italian children
41. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects
42. R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients
43. Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome
44. Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the “Rete Ematologica Lombarda”
45. A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
46. Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)
47. Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma
48. Selecting transplant in the elderly: validation of IMWG frailty score and Revised Myeloma Comorbidity Index compared to clinical judgment
49. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment
50. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.